Dr. DiNardo on the Results of the VIALE-A Trial in AML

Video

Courtney DiNardo, MD, MSCE, discusses the results of the phase 3 VIALE-A trial in acute myeloid leukemia (AML).

Courtney DiNardo, MD, MSCE, clinical researcher in the Department of Leukemia of the Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center, discusses the results of the phase 3 VIALE-A trial in acute myeloid leukemia (AML).

In VIALE-A, treatment-naïve patients who were ineligible for intensive therapy were randomized 2:1 to the combination of venetoclax (Venclexta) and azacitidine (n = 286) versus azacitidine alone (n = 145).

At a median follow-up of 20.5 months, the complete response (CR)/CR with incomplete hematologic recovery rates in the combination and azacitidine-alone arms were 66% and 28%, respectively (P <.001). The median time to first CR/CRi response was 1.3 and 2.8 months, respectively. The benefit with venetoclax was observed across all key subgroups, says DiNardo. The duration of CR/CRi was 17.5 months and 13.4 months respectively.

The median overall survival was 14.7 months in the combination arm versus 9.6 months in the azacitidine-alone arm (HR, 0.66; 95% CI, 0.52-0.85; P <.001), representing the first phase 3 trial to show such a clear survival advantage in this patient population, concludes DiNardo.

Related Videos
Patrick I. Borgen, MD
Kari Hacker, MD, PhD, NYU Grossman School of Medicine
Janos L. Tanyi, MD, PhD, associate professor, Obstetrics and Gynecology, Hospital of the University of Pennsylvania
Reshma Lillaney Mahtani, DO
Christian Marth, MD, PhD, head, professor, Department of Obstetrics and Gynecology, Innsbruck Medical University
Mansoor Raza Mirza, MD, chief oncologist, Department of Oncology, Rigshospitalet, Copenhagen University Hospital
Judy Hayek, MD, gynecologic oncology fellow, State University of New York (SUNY) Downstate College of Medicine
Leslie M. Randall, MD, MAS, professor, division head, Department of Obstetrics and Gynecology – Gynecologic Oncology, Virginia Commonwealth University School of Medicine Obstetrics and Gynecology
Dimitrios Nasioudis, MD, fellow, Gynecologic Oncology, Perelman School of Medicine, the University of Pennsylvania
Sara Corvigno, MD, PhD, translational researcher, oncology, The University of Texas MD Anderson Cancer Center